<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）在周一发布的研究报告中被 StockNews.com 的股票分析师从 “买入” 评级下调至 “持有” 评级。</p>
<p>其他研究分析师最近也对该公司发布了报告。Raymond James 在 12 月 19 日的研究报告中将 Prestige Consumer Healthcare 的评级上调至 “适度买入”。DA Davidson 在 2 月 7 日的研究报告中将 Prestige Consumer Healthcare 的目标价格从 95.00 美元提高至 104.00 美元，并给予该股票 “买入” 评级。Oppenheimer 在 2 月 13 日的研究报告中将 Prestige Consumer Healthcare 的目标价格从 87.00 美元提高至 93.00 美元，并给予该股票 “跑赢大盘” 评级。Canaccord Genuity Group 在 2 月 7 日的报告中将 Prestige Consumer Healthcare 的目标价格从 93.00 美元提高至 100.00 美元，并给予该公司 “买入” 评级。最后，Sidoti 在 12 月 9 日的报告中将 Prestige Consumer Healthcare 的评级从 “买入” 下调至 “中性”，并设定了 90.00 美元的目标价格。三位分析师对该股票给予了持有评级，三位分析师则给予了买入评级。根据 MarketBeat 的数据，Prestige Consumer Healthcare 目前的共识评级为 “适度买入”，共识目标价格为 92.60 美元。</p>
<p><strong>获取我们最新的 PBH 股票分析</strong></p>
<h2>Prestige Consumer Healthcare 价格表现</h2>
<p>周一，PBH 股票在交易中下跌 2.38 美元，报 86.64 美元。该公司的交易量为 535,883 股，而其平均交易量为 333,129 股。该公司的 50 日移动平均价格为 80.99 美元，200 日移动平均价格为 78.00 美元。该公司的流动比率为 3.68，速动比率为 2.20，债务与股本比率为 0.56。该公司的市值为 42.9 亿美元，市盈率为 20.29，市盈增长比率为 2.69，贝塔值为 0.46。Prestige Consumer Healthcare 的 52 周低点为 62.35 美元，52 周高点为 90.04 美元。</p>
<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近在 2 月 6 日发布了季度财报。该公司报告季度每股收益为 1.22 美元，超出分析师共识预期的 1.18 美元，超出幅度为 0.04 美元。Prestige Consumer Healthcare 的股本回报率为 12.36%，净利润率为 19.13%。股票研究分析师预计，Prestige Consumer Healthcare 在当前财政年度将发布 4.5 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近对该公司的持仓进行了调整。Kestra Investment Management LLC 在第四季度购买了 Prestige Consumer Healthcare 的新股份，价值约 27,000 美元。CIBC 私人财富集团在第四季度将其在 Prestige Consumer Healthcare 的股份增加了 48.9%。CIBC 私人财富集团目前拥有该公司 463 股股票，价值 34,000 美元，此前在上个季度又购买了 152 股。Headlands Technologies LLC 在第四季度购买了 Prestige Consumer Healthcare 的新职位，价值约 40,000 美元。亨廷顿国家银行在第三季度将其在 Prestige Consumer Healthcare 的股份增加了 39.9%。亨廷顿国家银行目前拥有 635 股该公司的股票，价值 46,000 美元，此前在上个季度又购买了 181 股。最后，McIlrath &amp; Eck LLC 在第四季度将其在 Prestige Consumer Healthcare 的持股增加了 19.1%。McIlrath &amp; Eck LLC 目前拥有该公司 959 股股票，价值 75,000 美元，此前在此期间又收购了 154 股。99.95% 的股票由机构投资者持有。</p>
<h2>关于 Prestige Consumer Healthcare</h2>
<p>（获取免费报告）</p>
<p>Prestige Consumer Healthcare Inc 及其子公司在美国和国际上开发、制造、营销、分销和销售非处方（OTC）健康和个人护理产品。该公司分为两个部门，北美 OTC 医疗保健和国际 OTC 医疗保健。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prestige Consumer Healthcare</li>
<li>如何从成长投资中获利</li>
<li>当通货膨胀上升时，如何保护您的投资组合</li>
<li>精通纪律：克服交易中的情绪挑战</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>尽管面临挑战，Novo Nordisk 计划击败 GLP-1 竞争对手</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在 Prestige Consumer Healthcare 吗？</h2>
<p>在您考虑 Prestige Consumer Healthcare 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prestige Consumer Healthcare 并不在名单上。</p>
<p>虽然 Prestige Consumer Healthcare 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

普雷斯蒂奇

<p>StockNews.com 已将 Prestige Consumer Healthcare（纽约证券交易所代码：PBH）评级从 “买入” 下调至 “持有”。其他分析师的看法不一，Raymond James 将其评级上调至 “适度买入”，而 DA Davidson 则将目标价提高至 104 美元。该股票交易价格下跌至 86.64 美元，市值为 42.9 亿美元，市盈率为 20.29。机构投资者持有该股票的 99.95%。Prestige Consumer Healthcare 在北美和国际市场开发和销售非处方健康产品</p>

<p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was downgraded by stock analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Monday.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）在周一发布的研究报告中被 StockNews.com 的股票分析师从 “买入” 评级下调至 “持有” 评级。</p>
</div><p>Other research analysts have also recently issued reports about the company. Raymond James raised Prestige Consumer Healthcare to a &#34;moderate buy&#34; rating in a research report on Thursday, December 19th. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, February 13th. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 7th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $92.60.</p>
<div class="lb-trans"><p>其他研究分析师最近也对该公司发布了报告。Raymond James 在 12 月 19 日的研究报告中将 Prestige Consumer Healthcare 的评级上调至 “适度买入”。DA Davidson 在 2 月 7 日的研究报告中将 Prestige Consumer Healthcare 的目标价格从 95.00 美元提高至 104.00 美元，并给予该股票 “买入” 评级。Oppenheimer 在 2 月 13 日的研究报告中将 Prestige Consumer Healthcare 的目标价格从 87.00 美元提高至 93.00 美元，并给予该股票 “跑赢大盘” 评级。Canaccord Genuity Group 在 2 月 7 日的报告中将 Prestige Consumer Healthcare 的目标价格从 93.00 美元提高至 100.00 美元，并给予该公司 “买入” 评级。最后，Sidoti 在 12 月 9 日的报告中将 Prestige Consumer Healthcare 的评级从 “买入” 下调至 “中性”，并设定了 90.00 美元的目标价格。三位分析师对该股票给予了持有评级，三位分析师则给予了买入评级。根据 MarketBeat 的数据，Prestige Consumer Healthcare 目前的共识评级为 “适度买入”，共识目标价格为 92.60 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PBH</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PBH 股票分析</strong></p>
</div><h2>Prestige Consumer Healthcare Price Performance</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 价格表现</h2>
</div><p>PBH stock traded down $2.38 during trading on Monday, hitting $86.64. The company had a trading volume of 535,883 shares, compared to its average volume of 333,129. The company has a fifty day moving average price of $80.99 and a two-hundred day moving average price of $78.00. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.29 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $90.04.</p>
<div class="lb-trans"><p>周一，PBH 股票在交易中下跌 2.38 美元，报 86.64 美元。该公司的交易量为 535,883 股，而其平均交易量为 333,129 股。该公司的 50 日移动平均价格为 80.99 美元，200 日移动平均价格为 78.00 美元。该公司的流动比率为 3.68，速动比率为 2.20，债务与股本比率为 0.56。该公司的市值为 42.9 亿美元，市盈率为 20.29，市盈增长比率为 2.69，贝塔值为 0.46。Prestige Consumer Healthcare 的 52 周低点为 62.35 美元，52 周高点为 90.04 美元。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近在 2 月 6 日发布了季度财报。该公司报告季度每股收益为 1.22 美元，超出分析师共识预期的 1.18 美元，超出幅度为 0.04 美元。Prestige Consumer Healthcare 的股本回报率为 12.36%，净利润率为 19.13%。股票研究分析师预计，Prestige Consumer Healthcare 在当前财政年度将发布 4.5 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently made changes to their positions in the business. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $27,000. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,000. Huntington National Bank lifted its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. Finally, McIlrath &amp; Eck LLC raised its holdings in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath &amp; Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares during the period. 99.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近对该公司的持仓进行了调整。Kestra Investment Management LLC 在第四季度购买了 Prestige Consumer Healthcare 的新股份，价值约 27,000 美元。CIBC 私人财富集团在第四季度将其在 Prestige Consumer Healthcare 的股份增加了 48.9%。CIBC 私人财富集团目前拥有该公司 463 股股票，价值 34,000 美元，此前在上个季度又购买了 152 股。Headlands Technologies LLC 在第四季度购买了 Prestige Consumer Healthcare 的新职位，价值约 40,000 美元。亨廷顿国家银行在第三季度将其在 Prestige Consumer Healthcare 的股份增加了 39.9%。亨廷顿国家银行目前拥有 635 股该公司的股票，价值 46,000 美元，此前在上个季度又购买了 181 股。最后，McIlrath &amp; Eck LLC 在第四季度将其在 Prestige Consumer Healthcare 的持股增加了 19.1%。McIlrath &amp; Eck LLC 目前拥有该公司 959 股股票，价值 75,000 美元，此前在此期间又收购了 154 股。99.95% 的股票由机构投资者持有。</p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>关于 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare Inc 及其子公司在美国和国际上开发、制造、营销、分销和销售非处方（OTC）健康和个人护理产品。该公司分为两个部门，北美 OTC 医疗保健和国际 OTC 医疗保健。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>How to Profit From Growth Investing</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prestige Consumer Healthcare</li>
<li>如何从成长投资中获利</li>
<li>当通货膨胀上升时，如何保护您的投资组合</li>
<li>精通纪律：克服交易中的情绪挑战</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>尽管面临挑战，Novo Nordisk 计划击败 GLP-1 竞争对手</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Prestige Consumer Healthcare 吗？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Prestige Consumer Healthcare 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prestige Consumer Healthcare 并不在名单上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prestige Consumer Healthcare 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

StockNews.com 将普雷斯蒂奇消费者健康公司（NYSE:PBH）的评级下调至持有